Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs
Bloomberg Businessweek
Focus on CNS Drug Development and Perspectives on a Big Deal
The hosts discuss the potential of asking the CEOs of Bristol or Karuna about the promising areas in CNS drug development, followed by insights from Laura Chico and Matthew Mox on the big deal and acquisition. The chapter concludes with information on where to find the podcast show.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
